X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

DHL Supply Chain investing $400 million to grow its U.S. pharmaceutical and medical device distribution network

Content Team by Content Team
4th February 2022
in Packaging & Logistic, Press Statements
DHL Supply Chain investing $400 million to grow its U.S. pharmaceutical and medical device distribution network

DHL Supply Chain, the global and North American contract logistics leader within Deutsche Post DHL Group, announced its Life Sciences and Healthcare (LSHC) sector is investing upwards of $400 million to expand its pharmaceutical and medical device distribution network footprint by 27 percent this year – nearly 3 million additional square feet. With the ultimate goal of bringing critical healthcare products closer to trade partners and patients, DHL Supply Chain’s new investment includes six new U.S. sites by the end of 2022. The investment includes costs to invest in new buildings and technology, as well as the fit-out and start-up of new or expanded operations.

“This latest investment in our Life Sciences and Healthcare sector is testament to our track record and pedigree for delivering unrivalled supply chain expertise to our partners,” said Jim Saponaro, President, Life Sciences & Healthcare, DHL Supply Chain North America. “This substantial expansion will only further deepen the connections between our customers and the patients they serve by providing best-in-class end-to-end supply chain solutions.”

The expansion will grow the list of DHL Supply Chain’s LSHC sites to 34 by the end of 2022, strategically located across the U.S. including; Atlanta, GA, Cincinnati, OH, Memphis, TN, Reno, NV and Lebanon, PA. The new builds will be fully licensed with temperature controlled space that supports pharmaceutical storage requirements. The sites will also allow integrated solutions for both packaging and managed transportation.

DHL Supply Chain boasts myriad services in the life sciences and healthcare sector, including warehousing, secondary packaging, managed transportation, and end-to-end supply chain management services. In fact, LSHC is the fastest growing sector at DHL Supply Chain.

DHL Supply Chain’s LSHC sector aligns with the organization’s Accelerated Digitalization agenda to drive mass deployment of new technology – a key differentiator to other competitors. This strategy enables DHL Supply Chain to continuously increase efficiency and changes the way supply chain operations are run by concentrating on mature technologies like collaborative robotics, autonomous guided vehicles, smart wearables and augmented reality. Automation technology responds to the ongoing labor shortage challenge – not as a replacement – but rather complements our ass

Previous Post

Emmes Supports New Collaboration to Accelerate COVID-19 Research for Children

Next Post

PCI Pharma Services Continues to Expand Sterile Fill-Finish Expertise with State-of-the-Art Equipment

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Next Post
PCI Pharma Services Continues to Expand Sterile Fill-Finish Expertise with State-of-the-Art Equipment

PCI Pharma Services Continues to Expand Sterile Fill-Finish Expertise with State-of-the-Art Equipment

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In